Journal article
Intravesical Therapy - BCG and Beyond
Bladder cancer, Vol.5(1), pp.73-80
01/01/2019
DOI: 10.3233/BLC-180198
Abstract
Non-muscle invasive bladder cancer is marked by frequent recurrences and a risk for progression to life threatening disease. Intravesical Bacillus Calmette Guerin (BCG), one of the earliest effective immunotherapies for cancer, remains the current standard for treating high-risk non-muscle invasive bladder cancer. Optimal treatment with BCG includes periodic 3 weekly maintenance instillations, often with dose reduction to minimize toxicity. However, despite its efficacy, treatment failure is common. Efforts to provide alternate and potentially more effective therapy for this disease include increased understanding of bladder cancer through molecular profiling, multi-agent intravesical chemotherapy, and novel forms of immunotherapy.
Details
- Title: Subtitle
- Intravesical Therapy - BCG and Beyond
- Creators
- H. Barton Grossman - The University of Texas MD Anderson Cancer CenterDonald Lamm - University of ArizonaGottfrid Sjodahl - Lund UniversityMichael O'Donnell - Univ Iowa, Dept Urol, Carver Coll Med, Iowa City, IA 52242 USANoah Hahn - Sidney Kimmel Comprehensive Cancer CenterAshish Kamat - The University of Texas MD Anderson Cancer Center
- Resource Type
- Journal article
- Publication Details
- Bladder cancer, Vol.5(1), pp.73-80
- DOI
- 10.3233/BLC-180198
- ISSN
- 2352-3727
- eISSN
- 2352-3727
- Publisher
- Ios Press
- Number of pages
- 8
- Grant note
- Leo & Anne Albert Institute for Bladder Cancer Care and Research
- Language
- English
- Date published
- 01/01/2019
- Academic Unit
- Urology
- Record Identifier
- 9984320065902771
Metrics
10 Record Views